174 related articles for article (PubMed ID: 15358589)
1. Molecular mechanisms of chemoprevention and therapy of cancer by retinoids.
Shen PF
Front Biosci; 2004 Sep; 9():2663-70. PubMed ID: 15358589
[TBL] [Abstract][Full Text] [Related]
2. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
Duprez E; Lillehaug JR; Gaub MP; Lanotte M
Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
4. Retinoids in chemoprevention and differentiation therapy.
Hansen LA; Sigman CC; Andreola F; Ross SA; Kelloff GJ; De Luca LM
Carcinogenesis; 2000 Jul; 21(7):1271-9. PubMed ID: 10874003
[TBL] [Abstract][Full Text] [Related]
5. Retinoids in cancer chemoprevention.
Okuno M; Kojima S; Matsushima-Nishiwaki R; Tsurumi H; Muto Y; Friedman SL; Moriwaki H
Curr Cancer Drug Targets; 2004 May; 4(3):285-98. PubMed ID: 15134535
[TBL] [Abstract][Full Text] [Related]
6. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment.
Park DJ; Chumakov AM; Vuong PT; Chih DY; Gombart AF; Miller WH; Koeffler HP
J Clin Invest; 1999 May; 103(10):1399-408. PubMed ID: 10330422
[TBL] [Abstract][Full Text] [Related]
7. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
8. Retinoids in cancer therapy and chemoprevention: promise meets resistance.
Freemantle SJ; Spinella MJ; Dmitrovsky E
Oncogene; 2003 Oct; 22(47):7305-15. PubMed ID: 14576840
[TBL] [Abstract][Full Text] [Related]
9. Retinoid target genes in acute promyelocytic leukemia.
Pitha-Rowe I; Petty WJ; Kitareewan S; Dmitrovsky E
Leukemia; 2003 Sep; 17(9):1723-30. PubMed ID: 12970771
[TBL] [Abstract][Full Text] [Related]
10. Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
Xu K; Guidez F; Glasow A; Chung D; Petrie K; Stegmaier K; Wang KK; Zhang J; Jing Y; Zelent A; Waxman S
Cancer Res; 2005 Sep; 65(17):7856-65. PubMed ID: 16140955
[TBL] [Abstract][Full Text] [Related]
11. Retinoid differentiation therapy in promyelocytic leukemia.
Chomienne C; Fenaux P; Degos L
FASEB J; 1996 Jul; 10(9):1025-30. PubMed ID: 8801163
[TBL] [Abstract][Full Text] [Related]
12. Retinoic Acid and Its Derivatives in Skin.
Szymański Ł; Skopek R; Palusińska M; Schenk T; Stengel S; Lewicki S; Kraj L; Kamiński P; Zelent A
Cells; 2020 Dec; 9(12):. PubMed ID: 33322246
[TBL] [Abstract][Full Text] [Related]
13. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia.
Cornic M; Delva L; Castaigne S; Lefebvre P; Balitrand N; Degos L; Chomienne C
Leukemia; 1994 Jun; 8(6):914-7. PubMed ID: 8207983
[TBL] [Abstract][Full Text] [Related]
14. Retinoid targets in cancer therapy and chemoprevention.
Dragnev KH; Petty WJ; Dmitrovsky E
Cancer Biol Ther; 2003; 2(4 Suppl 1):S150-6. PubMed ID: 14508093
[TBL] [Abstract][Full Text] [Related]
15. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
16. Cyclin proteolysis as a retinoid cancer prevention mechanism.
Dragnev KH; Freemantle SJ; Spinella MJ; Dmitrovsky E
Ann N Y Acad Sci; 2001 Dec; 952():13-22. PubMed ID: 11795432
[TBL] [Abstract][Full Text] [Related]
17. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
[TBL] [Abstract][Full Text] [Related]
18. Promyelocytic leukemia-specific PML-retinoic acid alpha receptor fusion protein interferes with erythroid differentiation of human erythroleukemia K562 cells.
Grignani F; Testa U; Fagioli M; Barberi T; Masciulli R; Mariani G; Peschle C; Pelicci PG
Cancer Res; 1995 Jan; 55(2):440-3. PubMed ID: 7529139
[TBL] [Abstract][Full Text] [Related]
19. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.
Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986
[TBL] [Abstract][Full Text] [Related]
20. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
